Cyclacel Pharma (CYCC) Tops Q2 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- US futures fall on tech selloff as concerns about hawkish Fed, AI spending mount
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Cyclacel Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
August 10, 2022 4:05 PM EDTÂ - Oral fadraciclib demonstrated good tolerability with continuous dosing;Â anticipate entering Phase 2 POC stage in 2H 2022
         - Demonstrated evidence of target engagement for CDK2 and CDK9
         - Company to host R&D day in fall of 2022 to highlight data updates          for fadraciclib and CYC140 in solid tumor Phase 1/2 studies
         - Cash runway into 2H 2023 -
               - Conference call scheduled for August 10, 2022 at 4:30 pm... More
